Sevrioukova Irina F, Poulos Thomas L
Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, 92697, USA,
Adv Exp Med Biol. 2015;851:83-105. doi: 10.1007/978-3-319-16009-2_3.
Cytochrome P450 3A4 (CYP3A4) is the major and most important drug-metabolizing enzyme in humans that oxidizes and clears over a half of all administered pharmaceuticals. This is possible because CYP3A4 is promiscuous with respect to substrate binding and has the ability to catalyze diverse oxidative chemistries in addition to traditional hydroxylation reactions. Furthermore, CYP3A4 binds and oxidizes a number of substrates in a cooperative manner and can be both induced and inactivated by drugs. In vivo, CYP3A4 inhibition could lead to undesired drug-drug interactions and drug toxicity, a major reason for late-stage clinical failures and withdrawal of marketed pharmaceuticals. Owing to its central role in drug metabolism, many aspects of CYP3A4 catalysis have been extensively studied by various techniques. Here, we give an overview of experimental and theoretical methods currently used for investigation and prediction of CYP3A4-ligand interactions, a defining factor in drug metabolism, with an emphasis on the problems addressed and conclusions derived from the studies.
细胞色素P450 3A4(CYP3A4)是人体内主要且最重要的药物代谢酶,可氧化并清除超过一半的所有施用药物。这之所以可能,是因为CYP3A4在底物结合方面具有多选择性,并且除了传统的羟基化反应外,还具有催化多种氧化化学反应的能力。此外,CYP3A4以协同方式结合并氧化多种底物,并且可被药物诱导和失活。在体内,CYP3A4抑制可能导致不良的药物-药物相互作用和药物毒性,这是晚期临床失败和已上市药物撤市的主要原因。由于其在药物代谢中的核心作用,CYP3A4催化的许多方面已通过各种技术进行了广泛研究。在此,我们概述了目前用于研究和预测CYP3A4-配体相互作用(药物代谢中的一个决定性因素)的实验和理论方法,重点关注所解决的问题和从研究中得出的结论。